Base de dados : MEDLINE
Pesquisa : D02.033.800.329.225 [Categoria DeCS]
Referências encontradas : 42 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 5 ir para página              

  1 / 42 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26647149
[Au] Autor:Oleske JB; Smith BT; Barber J; Weatherall JC
[Ad] Endereço:U.S. Department of Homeland Security, Transportation Security Laboratory, EMXLAB, Atlantic City International Airport, NJ 08405, USA.
[Ti] Título:Identifying Raman and Infrared Vibrational Motions of Erythritol Tetranitrate.
[So] Source:Appl Spectrosc;69(12):1397-402, 2015 Dec.
[Is] ISSN:1943-3530
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The vibrational bands of erythritol tetranitrate (ETN) were measured experimentally with both Raman spectroscopy and attenuated total reflectance Fourier transform infrared (ATR FT-IR) spectroscopy. Seventy-two (3N-6) vibrational modes were predicted for ETN using density functional theory calculations performed using the B3LYP/6-31G* density functional basis set and geometry optimization. Raman spectroscopy and ATR FT-IR were used to measure observable Raman and IR signatures between 140 and 3100 wavenumbers (cm(-1)). Within this spectral range, 32 Raman bands and 21 IR bands were measured and identified by their predicted vibrational motion. The spectroscopic and theoretical analysis of ETN performed will advance the detection and identification capabilities of field measuring instruments for this explosive.
[Mh] Termos MeSH primário: Tetranitrato de Eritritil/química
Substâncias Explosivas/química
Espectrofotometria Infravermelho/métodos
Análise Espectral Raman/métodos
[Mh] Termos MeSH secundário: Tetranitrato de Eritritil/análise
Substâncias Explosivas/análise
Modelos Moleculares
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Explosive Agents); 35X333P19D (Erythrityl Tetranitrate)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:151209
[Lr] Data última revisão:
151209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151210
[St] Status:MEDLINE
[do] DOI:10.1366/14-07684


  2 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19406636
[Au] Autor:Lange K; Koenig A; Roegler C; Seeling A; Lehmann J
[Ad] Endereço:Lehrstuhl für Pharmazeutische/Medizinische Chemie, Institut für Pharmazie, Friedrich-Schiller-Universität Jena, Jena, Thuringia, Germany.
[Ti] Título:NO donors. Part 18: Bioactive metabolites of GTN and PETN--synthesis and vasorelaxant properties.
[So] Source:Bioorg Med Chem Lett;19(11):3141-4, 2009 Jun 01.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The vasodilators glyceryl trinitrate (GTN) and pentaerythrityl tetranitrate (PETN) are supposed to be degraded in vivo to the lower nitrates PETriN, PEDN, PEMN, 1,2-GDN, 1,3-GDN, 1-GMN, and 2-GMN. We synthesized these bioactive metabolites as reference compounds for pharmacokinetic studies. The use of HPLC-methods for monitoring the stepwise reduction of PETN to lower nitrates and the syntheses of the glyceryl dinitrates proved advantageous. Furthermore, we measured the vasorelaxant properties of all metabolites by performing organ bath experiments with porcine pulmonary arteries. In general, the vasodilator potency increases with the number of nitrate moieties in the compound.
[Mh] Termos MeSH primário: Tetranitrato de Eritritil/metabolismo
Doadores de Óxido Nítrico/metabolismo
Nitroglicerina/metabolismo
Vasodilatadores/metabolismo
[Mh] Termos MeSH secundário: Animais
Tetranitrato de Eritritil/síntese química
Tetranitrato de Eritritil/farmacologia
Doadores de Óxido Nítrico/síntese química
Doadores de Óxido Nítrico/farmacologia
Nitroglicerina/síntese química
Nitroglicerina/farmacologia
Artéria Pulmonar/efeitos dos fármacos
Artéria Pulmonar/fisiologia
Suínos
Vasodilatação/efeitos dos fármacos
Vasodilatadores/síntese química
Vasodilatadores/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Nitric Oxide Donors); 0 (Vasodilator Agents); 35X333P19D (Erythrityl Tetranitrate); G59M7S0WS3 (Nitroglycerin)
[Em] Mês de entrada:0907
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090502
[St] Status:MEDLINE
[do] DOI:10.1016/j.bmcl.2008.04.057


  3 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10024078
[Au] Autor:Rigamonti AE; Cella SG; Marazzi N; Müller EE
[Ad] Endereço:Department of Medical Pharmacology, University of Milan, Italy.
[Ti] Título:Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs.
[So] Source:Metabolism;48(2):176-82, 1999 Feb.
[Is] ISSN:0026-0495
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The growth hormone (GH)-releasing activity of Hexarelin, a potent GH-releasing peptide (GHRP) analog, was evaluated in eight young (aged 1 to 6 years) and five old (10 to 16 years) beagle dogs pretreated with erythrityl tetranitrate, a liposoluble nitric oxide (NO) donor, and/or indomethacin, an inhibitor of cyclooxygenase enzymes, and N-nitro-L- or N-nitro-D-arginine methylester (L-NAME and D-NAME), active and inactive NO synthase (NOS) inhibitors, respectively. Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P < .01) and aged animals (314.82 +/- 117.11 v 1,314.12 +/- 484.75 ng x mL(-1) x h, P < .01). The NO donor alone did not modify baseline GH levels in either young dogs (188.68 +/- 85.24 ng x mL(-1) x h) or old dogs (120.49 +/- 22.03 ng x mL(-1) x h). L-NAME (5 mg x kg(-1) x 2 i.v.) suppressed GH release induced by the peptide in young dogs (1,367.68 +/- 251.87 v 411.12 +/- 68.49 ng x mL(-1) x h, P < .01), but potentiated it in old dogs (314.73 +/- 117.10 v 1,103.97 +/- 374.11 ng x mL(-1) x h, P < .01). D-NAME (5 mg x kg(-1) x 2 i.v.) did not affect the GH response to Hexarelin in either young (1,328.68 +/- 433.54 ng x mL(-1) x h) or aged (342.32 +/- 84.82 ng x mL(-1) x h) dogs. Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS). In conclusion, (1) NO donors are capable to further increase the strong GH-releasing activity of Hexarelin in both young and old dogs, although the site(s) and mechanism(s) of action of NO is still obscure; (2) the different GH response to the peptide after NOS inhibition in young and old dogs signifies in the latter an alteration of the somatotrope function; and (3) prostaglandins are the downstream effectors of the chain of events triggered by activation of the NO-ergic system.
[Mh] Termos MeSH primário: Envelhecimento/metabolismo
Hormônio do Crescimento/metabolismo
Substâncias de Crescimento/farmacologia
Óxido Nítrico/fisiologia
Oligopeptídeos/farmacologia
[Mh] Termos MeSH secundário: Animais
Área Sob a Curva
Inibidores de Ciclo-Oxigenase/farmacologia
Cães
Inibidores Enzimáticos/farmacologia
Tetranitrato de Eritritil/farmacologia
Feminino
Indometacina/farmacologia
Masculino
NG-Nitroarginina Metil Éster/farmacologia
Óxido Nítrico Sintase/antagonistas & inibidores
Radioimunoensaio
Vasodilatadores/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cyclooxygenase Inhibitors); 0 (Enzyme Inhibitors); 0 (Growth Substances); 0 (Oligopeptides); 0 (Vasodilator Agents); 09QF37C617 (hexarelin); 31C4KY9ESH (Nitric Oxide); 35X333P19D (Erythrityl Tetranitrate); 9002-72-6 (Growth Hormone); EC 1.14.13.39 (Nitric Oxide Synthase); V55S2QJN2X (NG-Nitroarginine Methyl Ester); XXE1CET956 (Indomethacin)
[Em] Mês de entrada:9902
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990219
[St] Status:MEDLINE


  4 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10180293
[Ti] Título:Erythrityl tetranitrate; drug efficacy study implementation; revocation of exemption; opportunity for a hearing--FDA. Notice.
[So] Source:Fed Regist;63(120):34188-90, 1998 Jun 23.
[Is] ISSN:0097-6326
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The Food and Drug Administration (FDA) is revoking the temporary exemption that has allowed single-entity coronary vasodilator drug products containing erythrityl tetranitrate to remain on the market beyond the time limits scheduled for implementation of the Drug Efficacy Study. FDA is announcing that the products lack substantial evidence of effectiveness and is offering an opportunity for a hearing on a proposal to withdraw approval of any applicable new drug applications (NDA's) or abbreviated new drug applications (ANDA's).
[Mh] Termos MeSH primário: Aprovação de Drogas/legislação & jurisprudência
Tetranitrato de Eritritil/uso terapêutico
Aplicação de Novas Drogas em Teste/legislação & jurisprudência
Vasodilatadores/uso terapêutico
[Mh] Termos MeSH secundário: Seres Humanos
Resultado do Tratamento
Estados Unidos
United States Food and Drug Administration
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Vasodilator Agents); 35X333P19D (Erythrityl Tetranitrate)
[Em] Mês de entrada:9807
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:H
[Da] Data de entrada para processamento:980529
[St] Status:MEDLINE


  5 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9918783
[Au] Autor:Hinz B; Kuntze U; Schröder H
[Ad] Endereço:Department of Pharmacology and Toxicology, School of Pharmacy, Martin Luther University, Halle (Saale), Germany.
[Ti] Título:Pentaerithrityl tetranitrate and its phase I metabolites are potent activators of cellular cyclic GMP accumulation.
[So] Source:Biochem Biophys Res Commun;253(3):658-61, 1998 Dec 30.
[Is] ISSN:0006-291X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Using pig kidney epithelial cells (LLC-PK1), the present study assesses the cyclic GMP stimulatory effect of pentaerithrityl tetranitrate and its metabolites in comparison to other therapeutically used nitric oxide donors. Pentaerithrityl tetranitrate was found to be the most potent activator of cyclic GMP synthesis compared to other clinically relevant organic nitrates (glyceryl trinitrate, isosorbide dinitrate, isosorbide-5-mononitrate). The phase I metabolite pentaerithrityl trinitrate was equipotent with its parent compound in stimulating cyclic GMP. The concentration-response curves of pentaerithrityl dinitrate and isosorbide dinitrate for cyclic GMP accumulation were virtually identical. In contrast, pentaerithrityl mononitrate and the phase II metabolite pentaerithrityl trinitrate glucuronide did not alter basal cyclic GMP levels. It is concluded that the long-term vasodilatory and antiischemic effects of pentaerithrityl tetranitrate are caused to a substantial extent by cyclic GMP-mediated actions of its pharmacologically active phase I metabolites.
[Mh] Termos MeSH primário: GMP Cíclico/biossíntese
Tetranitrato de Eritritil/análogos & derivados
Guanilato Ciclase/metabolismo
Doadores de Óxido Nítrico/farmacologia
[Mh] Termos MeSH secundário: Animais
Células Cultivadas
Ativação Enzimática
Células Epiteliais/citologia
Dinitrato de Isossorbida/farmacologia
Rim/citologia
Suínos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Nitric Oxide Donors); 35X333P19D (Erythrityl Tetranitrate); EC 4.6.1.2 (Guanylate Cyclase); H2D2X058MU (Cyclic GMP); IA7306519N (Isosorbide Dinitrate)
[Em] Mês de entrada:9902
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990127
[St] Status:MEDLINE


  6 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:3152793
[Au] Autor:Campa PP
[Ti] Título:[Nitroderivatives. Novelty on old drugs].
[Ti] Título:I nitroderivati. Novità su vecchi farmaci..
[So] Source:Ann Ital Med Int;2(3):236-41, 1987 Jul-Sep.
[Is] ISSN:0393-9340
[Cp] País de publicação:Italy
[La] Idioma:ita
[Mh] Termos MeSH primário: Tetranitrato de Eritritil/uso terapêutico
Dinitrato de Isossorbida/uso terapêutico
Nitroglicerina/uso terapêutico
Tetranitrato de Pentaeritritol/uso terapêutico
[Mh] Termos MeSH secundário: Doença das Coronárias/tratamento farmacológico
Formas de Dosagem
Insuficiência Cardíaca/tratamento farmacológico
Seres Humanos
Dinitrato de Isossorbida/análogos & derivados
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Dosage Forms); 10L39TRG1Z (Pentaerythritol Tetranitrate); 35X333P19D (Erythrityl Tetranitrate); G59M7S0WS3 (Nitroglycerin); IA7306519N (Isosorbide Dinitrate)
[Em] Mês de entrada:9010
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:870701
[St] Status:MEDLINE


  7 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:6491957
[Au] Autor:Olsen CS; Scroggins HS
[Ti] Título:High-performance liquid chromatographic determination of the nitrate esters isosorbide dinitrate, pentaerythritol tetranitrate, and erythrityl tetranitrate in various tablet forms.
[So] Source:J Pharm Sci;73(9):1303-4, 1984 Sep.
[Is] ISSN:0022-3549
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A reliable, sensitive, and specific assay for isosorbide dinitrate pentaerythritol tetranitrate, and erythrityl tetranitrate in sublingual, uncoated, sustained-release, and chewable dosage forms, using high-performance liquid chromatography, is described. The nitrate ester dosage forms were dissolved in methanol, filtered, and injected directly into the liquid chromatograph. A variable-wavelength UV detector, operated at 220 nm, and a reverse-phase C18 microporous silica column were employed. The mobile phase was methanol-water (40:60). The proposed method is quantitative and reproducible.
[Mh] Termos MeSH primário: Tetranitrato de Eritritil/análise
Dinitrato de Isossorbida/análise
Tetranitrato de Pentaeritritol/análise
[Mh] Termos MeSH secundário: Cromatografia Líquida de Alta Pressão
Comprimidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Tablets); 10L39TRG1Z (Pentaerythritol Tetranitrate); 35X333P19D (Erythrityl Tetranitrate); IA7306519N (Isosorbide Dinitrate)
[Em] Mês de entrada:8411
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:840901
[St] Status:MEDLINE


  8 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:6351027
[Au] Autor:Nakamura Y; Haffty BG; Long RA; Hull HJ; Starbuck RR; Spodick DH
[Ti] Título:Erythrityl tetranitrate compared with isosorbide dinitrate. Effects on systolic time intervals and nitrate modification of effects of food.
[So] Source:Pharmacotherapy;3(4):230-4, 1983 Jul-Aug.
[Is] ISSN:0277-0008
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The pharmacologic effects of erythrityl tetranitrate (ETN) and isosorbide dinitrate (ISDN) were compared to placebo using systolic time intervals (STI) in a randomized, double-blind study in 15 fasted male volunteers. Sublingual doses of ETN 5 mg, ISDN 5 mg, and placebo were administered to each volunteer at weekly intervals, and measurements of heart rate and STI [pre-ejection period (PEP), left ventricular ejection time (LVET), and PEP/LVET ratio] were made serially for up to 6 hours after each dose. STI were determined using ear densitography. Evaluation of the pharmacologic effects of ETN and ISDN were based on placebo-corrected changes from baseline values. Ejection time index (ETI) [LVET corrected for heart rate] was shortened, but the changes were not statistically significant for either drug. However, after ETN and ISDN, statistically significant (p less than 0.05) changes in PEP and PEP/LVET ratio were demonstrated for up to 240 minutes after dosing. Unexpected marked changes in the baseline corrected PEP/LVET ratio were observed following food at 4 hours after dosing. This suggests increased inotropy during the postprandial period.
[Mh] Termos MeSH primário: Ingestão de Alimentos
Tetranitrato de Eritritil/farmacologia
Dinitrato de Isossorbida/farmacologia
Contração Miocárdica/efeitos dos fármacos
Sístole/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Ensaios Clínicos como Assunto
Seres Humanos
Masculino
Distribuição Aleatória
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
35X333P19D (Erythrityl Tetranitrate); IA7306519N (Isosorbide Dinitrate)
[Em] Mês de entrada:8310
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:830701
[St] Status:MEDLINE


  9 / 42 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:7068934
[Au] Autor:Haffty BG; Nakamura Y; Long RA; Hull JH; Spodick DH
[Ti] Título:Bioavailability of organic nitrates: a comparison of methods for evaluating plethysmographic responses.
[So] Source:J Clin Pharmacol;22(2-3):117-24, 1982 Feb-Mar.
[Is] ISSN:0091-2700
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Erythrityl tetranitrate, a long-acting organic nitrate, was compared with isosorbide dinitrate in a double-blind, placebo-controlled complete crossover study in 15 healthy male volunteers. A digital plethysmogram and ear densitogram were used to assess the physiologic response to these two sublingual nitrates, with the intensity and duration of drug effect calculated by differences in diastolic amplitude intensity before and after drug administration. Both 5 mg sublingual erythrityl tetranitrate and 5 mg isosorbide dinitrate produced significant increases in diastolic amplitude intensity for up to 3 hours. The erythrityl tetranitrate peak effect was less than that of the isosorbide dinitrate, but the incidence of headaches was also less. The ear densitogram was found to be an effective means of assessing the diastolic amplitude intensity changes.
[Mh] Termos MeSH primário: Nitratos/metabolismo
Pletismografia/métodos
Vasodilatação/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Disponibilidade Biológica
Pressão Sanguínea/efeitos dos fármacos
Método Duplo-Cego
Eletrocardiografia
Tetranitrato de Eritritil/metabolismo
Seres Humanos
Dinitrato de Isossorbida/metabolismo
Cinética
Masculino
Nitratos/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Nitrates); 35X333P19D (Erythrityl Tetranitrate); IA7306519N (Isosorbide Dinitrate)
[Em] Mês de entrada:8206
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:820201
[St] Status:MEDLINE


  10 / 42 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:6803194
[Au] Autor:Carile L; Laquaglia GA; Martone P; Marchionni F; Di Falco C
[Ti] Título:[Clinical and statistical study of 121 cases of acute myocardial infarct from 1976 to 1981 (month of April). Critical review].
[Ti] Título:Studio clinico-statistico su 121 casi di infarto miocardico acuto (IMA) dal 1976 al 1981 (mese di aprile). Revisione critica..
[So] Source:Minerva Med;73(14):821-7, 1982 Apr 02.
[Is] ISSN:0026-4806
[Cp] País de publicação:Italy
[La] Idioma:ita
[Ab] Resumo:The authors realized a retrospective clinical-statistical study about 121 cases of acute myocardial infarction (AMI), treated in the Department of general medicine with a pharmacological association of Lysine acetylsalicylate--Erythrityl tetranitrate--Papaverine hydrochloride, with the purpose of obtaining a vasodilatation on coronary arteries and a platelet antiaggregation, in the light of the new etiopathogenetic views about the prolonged coronary spasm and the platelet aggregation, in some cases of myocardial infarction with or without thrombosis. Obtained data are very optimistic about incidence of left ventricular insufficiency and (of) thromboembolisms, to they augur the sistematic adoption of this treatment of AMI, especially as to the early antiaggregation therapy.
[Mh] Termos MeSH primário: Aspirina/análogos & derivados
Tetranitrato de Eritritil/uso terapêutico
Lisina/análogos & derivados
Infarto do Miocárdio/tratamento farmacológico
Papaverina/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Aspirina/uso terapêutico
Vasos Coronários/efeitos dos fármacos
Feminino
Insuficiência Cardíaca/prevenção & controle
Seres Humanos
Lisina/uso terapêutico
Masculino
Meia-Idade
Agregação Plaquetária/efeitos dos fármacos
Estudos Retrospectivos
Tromboembolia/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
35X333P19D (Erythrityl Tetranitrate); DAA13NKG2Q (Papaverine); K3Z4F929H6 (Lysine); R16CO5Y76E (Aspirin); XAN4V337CI (acetylsalicylic acid lysinate)
[Em] Mês de entrada:8206
[Cu] Atualização por classe:161123
[Lr] Data última revisão:
161123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:820402
[St] Status:MEDLINE



página 1 de 5 ir para página              
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde